Prion infection induces conformational conversion of the normal prion protein PrP C , into the pathogenic isoform PrP 
, in prion diseases. It has been shown that PrP-knockout (Prnp These results indicate that MHM2D23-88 itself might either lose or greatly reduce the converting capacity to MHM2 Sc D23-88, and that the co-expressing wild-type PrP C can stimulate the conversion of MHM2D23-88 to MHM2 Sc D23-88 in trans. In the present study, we confirmed that Tg(MHM2D23-88)/Prnp 0/0 mice remained resistant to RML prions for up to 730 days after inoculation. However, we found that Tg(MHM2D23-88)/Prnp 0/0 mice were susceptible to 22L prions, developing the disease with prolonged incubation times and accumulating MHM2
Sc D23-88 in their brains. We also found accelerated conversion of MHM2D23-88 into MHM2 Sc D23-88 in the brains of RML-and 22L-inoculated Tg(MHM2D23-88)/Prnp 0/+ mice. However, wildtype PrP Sc accumulated less in the brains of these inoculated Tg(MHM2D23-88)/Prnp 0/+ mice, compared with RML-and 22L-inoculated Prnp 0/+ mice. These results show that MHM2D23-88 itself can convert into MHM2 Sc D23-88 without the help of the trans-acting PrP C , and that, irrespective of prion strains inoculated, the co-expressing wild-type PrP C stimulates the conversion of MHM2D23-88 into MHM2 Sc D23-88, but to the contrary, the co-expressing MHM2D23-88 disturbs the conversion of wild-type PrP C into PrP Sc .
Introduction
Prions are causative agents of transmissible spongiform encephalopathies, or prion diseases, a group of fatal neurodegenerative disorders, which include Creutzfeldt-Jakob disease in humans and scrapie and bovine spongiform encephalopathy in animals [1, 2] . It is believed that prions mainly consist of the abnormally folded, relatively proteinase K (PK)-resistant pathogenic isoform of prion protein, designated PrP Sc [1, 2] . PrP Sc is produced by conformational conversion of the normal cellular isoform of PrP, PrP C , via intermolecular interaction of both molecules [1, 2] . PrP C is a membrane glycoprotein tethered to the cell surface via a glycosylphosphatidylinositol moiety and expressed most abundantly in the central nervous system, particularly by neurons [3, 4] . We and others have shown that mice devoid of PrP C (Prnp 0/0 ) are resistant to prions, neither developing the disease nor producing PrP Sc or propagating the prions even after inoculation with the prions [5, 6, 7, 8] . These results indicate that the conversion of PrP C into PrP Sc is an essential event in the pathogenesis of prion disease.
A reverse genetic approach using reconstituted Prnp 0/0 mice with transgenes encoding various deletion mutants of PrP C is useful to investigate the structure-function relationship of PrP C conversion to PrP Sc . Prnp 0/0 mice expressing mouse PrP with Nterminal residues 23-88 deleted, or Tg(PrPD23-88)/Prnp 0/0 mice, developed prion disease after inoculation with RML scrapie prions, with accumulation of PrP Sc D23-88 in their brains [9] .
However, onset of the disease was delayed and the conversion of PrPD23-88 into PrP Sc D23-88 was inefficient [9] . These results indicate that the N-terminal residues affect the conversion of PrP C into PrP Sc . Delayed onset of the disease was also observed in Tg(MHM2)/Prnp 0/0 mice inoculated with RML prions [9] . MHM2 is a mouse (M)-hamster (H) chimeric PrP, with hamster PrP-derived methionine residues at 108 and 111 instead of leucine and valine residues of mouse PrP, indicating that the chimeric region also affects the conversion. MHM2D23-88 is chimeric MHM2 with the deletion of N-terminal residues 23-88. Interestingly, Tg(MHM2D23-88)/Prnp 0/0 mice were reported to remain healthy for more than 500 days after inoculation with RML prions [9, 10] . No MHM2 Sc D23-88 was accumulated in their brains [9, 10] 
Materials and Methods

Ethics statements
The Ethics Committee of Animal Care and Experimentation of the University of Occupational and Environmental Health, Kitakyushu, Japan, approved this study (approval number AE08-013). Animals were cared for in accordance with The Guiding Principle for Animal Care and Experimentation of the University of Occupational and Environmental Health and Japanese Law for Animal Welfare and Care.
Animals
Tg(MHM2D23-88)/Prnp 0/0 mice with the C57BL/ 66129Sv6FVB mixed background were produced elsewhere [11] . Tg(MHM2D23-88)/Prnp 0/+ and Prnp 0/+ mice [12] were obtained by mating Tg(MHM2D23-88)/Prnp 0/0 mice with C57BL/6 mice (CLEA Japan, Tokyo, Japan). ICR mice were purchased from Charles River Laboratories, Japan.
Prion inoculation
Brains were removed from terminally ill C57BL/6 mice infected with RML or 22L prions. A single brain was homogenized (10%, w/v) in phosphate-buffered saline (PBS) by passing it through 18 to 26 gauge needles and then diluted to 1% with PBS. Four to five week-old mice were intracerebrally inoculated with a 20 ml-aliquot of the homogenates.
Prion titration
10% (w/v) brain homogenates of RML-or 22L-infected, terminally ill C57BL/6 mice were serially diluted 10-fold with PBS, ranging from 10 21 to 10 26 in PBS, and a 20 ml-aliquot of 10 21 -, 10 24 -, 10 25 -, and 10
26
-diluted homogenates was intracerebrally inoculated into C57BL/6 mice aged 4-5 weeks. The mice were observed until 1 year after inoculation. The ID 50 /gram of the tissue was determined according to the method of Reed and Muench [13] . The data were statistically analyzed using logistic regression analysis.
Western blotting
Tissue homogenates (10%, w/v) were prepared in lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 0.5% Triton X-100, 0.5% sodium deoxycholate, 1 mM EDTA, and protease inhibitor mixture (Nakalai Tesque Co., Kyoto, Japan) using a Multi-beads shocker (Yasui Kikai Co., Osaka, Japan). Protein concentrations were determined using the BCA protein assay kit (Pierce, Rockford, USA.). Total proteins were treated with or without PK (Wako Pure Chemical Industries, Ltd., Osaka, Japan) at 20 mg/ml for 30 min at 37uC, electrophoresed through an SDS-polyacrylamide gel, and electrically transferred to an Immobilon-P PVDF membrane (Millipore Corp., MA, USA). The membrane was immersed in 5% non-fat dry milk-containing TBST (0.1% Tween-20, 100 mM NaCl, 10 mM Tris-HCl, pH 7.6) for 1 h at room temperature (RT), and incubated with M20 goat polyclonal antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 3F4 monoclonal antibody (Signet Laboratories Inc., Dedham, MA), or anti-b-actin monoclonal antibody (SigmaAldrich, Inc., St. Louis, MO) for 2 h at RT or overnight at 4uC in 1% non-fat dry milk-containing TBST. The membrane was washed in TBST several times. Signals were visualized using horseradish peroxidase-conjugated anti-mouse IgG antibodies (Amersham Biosciences Inc., Piscataway, NJ) and anti-goat IgG antibodies (CHEMICON International, Inc., Temecula, CA) and Immobilon Western Chemiluminescent HRP substrate (Millipore), and then detected using a chemiluminescence image analyzer, LAS-4000 mini (Fujifilm Co., Tokyo, Japan).
Hematoxylin-eosin staining
Paraffin-embedded samples were sectioned at 5 mm. The sectioned samples were deparaffinized, rehydrated, and stained with Mayer's hematoxylin solution (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and 1% Eosin Y solution (Wako Pure Chemical Industries, Ltd.). After washing, the samples were mounted with Softmount (Wako Pure Chemical Industries, Ltd.).
Vector constructions
The DNA fragment encoding mouse PrP residues 104-254 with methionine substitutions at codons 108 and 111 was first amplified by polymerase chain reaction (PCR) with a sense primer (59-ccaaaaaccaacatgaagcaca-39) and an antisense primer (59-cctctagacctcatcccacgatcaggaaga-39; the underlined sequence is an Xba I site; the bold sequence is a stop codon) using pcDNA3.1-moPrP plasmid [14] as a template. The resulting DNA fragment was then utilized as a 39 primer together with a sense primer (59-tcggatccagtcatcatggcgaaccttggc-39; the underlined sequence is a BamH I site; the bold sequence is a start codon) to amplify a DNA fragment encoding full-length mouse PrP with the methionine substitutions using the pcDNA3.1-moPrP template plasmid. After confirmation of the DNA sequences, the DNA fragment was digested by BamH I and Xba I and introduced into a pcDNA3.1 vector (Invitrogen, Carlsbad, CA) to generate pcDNA3.1-MHM2. Finally, to construct E. coli expression vectors for recombinant full-length MHM2 and MHM2D23-88, the corresponding DNA fragments were amplified by Phusion High-Fidelity DNA Polymerase (Thermo Scientific, Waltham, MA) using pcDNA3.1-MHM2 plasmid template with sense primers (59-ctcggatccaaaaagcggccaaagcctgga-39 for MHM2, the underlined sequence is a BamH I site; the italic sequence, residues 23-29 of mouse PrP; 59-ctcggatccggccaaggagggggtacccat-39 for MHM2D23-88, the underlined sequence is a BamH I site; the italic sequence, residues 89-95 of mouse PrP) and an antisense primer (59-ctcaagctttcatcccacgatcaggaagat-39, the underlined sequence is a Hind III site; the bold sequence is a stop codon; the italic sequence, residues 249-254 of mouse PrP). After confirmation of the DNA sequences, the DNA fragments were digested by BamH I and Hind III and introduced into a pQE30 vector (Qiagen, Hilden, Germany) to generate pQE30-MHM2 and pQE30-MHM2D23-88. To decrease the urea concentration in the suspension in a stepwise fashion, the Ni-NAT agarose pellet was suspended in 9 mL of the 8 M urea solution and 1 mL of dilution solution (0.1 M NaH 2 PO 4 , 0.01 M Tris, pH 6.3). The suspension was rotated at 4uC for 30 min and centrifuged (5006g, 3 min, 4uC). 1 mL of the resulting supernatant was removed, 1 mL of the dilution solution was instead added to the supernatant, and the diluted supernatant was rotated at 4uC for 30 min and centrifuged (5006g, 3 min, 4uC). This dilution procedure was repeated 13 times in total. After the last dilution step, the Ni-NAT agarose was washed 3 times with 10 mL of 2 M Urea solution (0.1 M NaH 2 PO 4 , 0.01 M Tris, 2 M urea, pH 6.3) containing 0.2% Triton X-100 and 3 times with 10 mL of 10 mM imidazole solution (50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole, pH 8.0) containing 0.2% Triton X-100. Finally, recombinant proteins were eluted from the Ni-NAT agarose in 560.4 mL of 0.5 M imidazole solution (50 mM NaH 2 PO 4 , 300 mM NaCl, 0.5 M imidazole, pH 8.0) containing 0.2% Triton X-100. The eluted proteins were further purified with a Superdex 200 gel filtration column (Life Technologies, Carlsbad, CA) with GF buffer [20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 0.15 M KCl, 1 mM dithiothreitol, 5% glycerol, 0.2% Triton X-100].
Purification of recombinant proteins
Pull-down assay
Clarified brain homogenate was prepared as follows. 5% (w/v) brain homogenate in PBS was sonicated for 1 min and centrifuged at 5006g for 15 min at 4uC. The supernatant was collected and diluted with PBS to 3 mg-protein/ml. Anti-His4 ab-Protein G beads were prepared as follows. Anti-His4 antibody (Qiagen) (0.3 mg) was incubated with 10 mL of Dynabeads Protein G (Life technologies) in 200 mL of binding buffer (PBS containing 1% Triton X-100 and 1% Tween 20) at RT. After 1 h-incubation, the beads were washed with the binding buffer to remove unbound antibody. The purified His-tagged recombinant PrP was incubated with 75 mg of the clarified brain homogenate in the binding buffer containing 2 M urea at 4uC for 1 h. The anti-His4 ab-Protein G beads were added and the mixture was rotated at 4uC for 4 h. The immune complexes were collected using a magnetic separation rack and washed with wash buffer (PBS containing 0.05% Triton X-100 and 0.05% Tween 20) . After washing, the complexes were incubated in 30 mL of lysis buffer (150 mM NaCl, 50 mM TrisHCl, pH 7.5, 0.5% Triton X-100, 0.5% sodium deoxycholate, 1 mM EDTA) containing 50 mg/ml of PK at 37uC for 30 min. The PK-treated samples were subjected to Western blotting.
Results
Tg(MHM2D23-88)/Prnp
0/0 mice develop prion disease after inoculation with 22L prions, but not with RML prions , and Prnp 0/+ mice. We previously reported that Prnp 0/0 mice used in this study developed cerebellar ataxia at 469646 days after birth due to ectopic expression of a PrP-like molecule Dpl in their brains [12, 14] , and that the ataxia was not rescued in Tg(MHM2D23-88)/Prnp 0/0 mice [11] . Therefore, to avoid false diagnosis of symptoms specifically developed in inoculated Tg(MHM2D23-88)/Prnp 0/0 mice, we reared the inoculated mice together with uninoculated age-matched Prnp 0/0 mice at the same time and carefully compared the symptoms appearing in inoculated Tg(MHM2D23-88)/Prnp 0/0 mice to those in un-inoculated Prnp 0/0 mice. No specific symptoms other than the ataxia were observed in Tg(MHM2D23-88)/Prnp 0/0 mice more than 730 days post-inoculation (dpi) with RML prions (Table 1 ). In contrast, Tg(MHM2D23-88)/Prnp 0/0 mice inoculated with 22L prions developed specific symptoms, such as decreased locomotion, urinary incontinence, ruffled body hair and, in some male cases, priapism with incubation times at 538629 dpi (Table 1) . Tg(MHM2D23-88)/Prnp 0/+ and Prnp 0/+ mice also developed the disease at 347616 and 393613 dpi with RML prions and at 27762 and 27261 dpi with 22L prions, respectively (Table 1) . We repeated the same experiments with increased numbers of mice and obtained consistent results (Table 1) .
There is a possibility that the different susceptibility of Tg(MHM2D23-88)/Prnp 0/0 mice to RML and 22L prions might not be due to different responsiveness of MHM2D23-88 to RML and 22L prions, but rather due to different infectious doses of RML and 22L prions inoculated. To rule out this possibility, we determined infectious titers in the brain homogenates from RMLor 22L-infected, terminally ill C57BL/6 mice that were similarly prepared as the brain homogenates used as inocula. The serially diluted brain homogenates were intracerebrally inoculated into C57BL/6 mice. No significant difference was detected in the number of diseased mice between the groups inoculated with each dilution of RML-and 22L-infected brain homogenates (Logistic regression analysis, p = 0.083, Table 2 ), indicating that infectious titers are not different in the RML-and 22L-infected brain homogenates used (Table 2 ). According to the method of Reed and Muench [13] , ID 50 /gram of the brain tissue was calculated as 10 7.7 and 10 8.2 in the RML-and 22L-infected brain homogenates, respectively ( Table 2 ). These results indicate that the different susceptibility of Tg(MHM2D23-88)/Prnp 0/0 mice to RML and 22L prions is due to different responsiveness of MHM2D23-88 to RML and 22L prions. C57BL/6 mice inoculated with RML and 22L prions developed the disease with similar incubation times ( Table 2 ). However, RML-inoculated Prnp 0/+ mice showed longer incubation times than 22L-inoculated Prnp 0/+ mice ( Table 1) . These results suggest that RML and 22L prions are affected in their propagation by the expression levels of PrP C , with RML prions being affected more strongly than 22L prions.
We then investigated the brain sections from these inoculated mice for spongiosis, a pathological hallmark of prion disease. The sections were subjected to hematoxylin-eosin staining. Spongiosis was easily detectable in the brains of 22L-inoculated, terminally ill Tg(MHM2D23-88)/Prnp 0/0 (n = 3), Tg(MHM2D23-88)/Prnp 0/+ (n = 4), and Prnp 0/+ mice (n = 3), particularly in the cerebral cortex, hippocampus, thalamus, and cerebellum ( Fig. 1A and S1A). It was mild in Tg(MHM2D23-88)/Prnp 0/0 mice compared to that in Tg(MHM2D23-88)/Prnp 0/+ and Prnp 0/+ mice ( Fig. 1A  and S1A ). Spongiosis was also observed in the sections of RMLinoculated, terminally ill Tg(MHM2D23-88)/Prnp 0/+ (n = 4) and Prnp 0/+ mice (n = 4) ( Fig. 1B and S1B ). However, spongiosis was hardly detectable in Tg(MHM2D23-88)/Prnp 0/0 mice, which were inoculated with RML prions and sacrificed at 419 (n = 2) and 595 dpi (n = 1) (Fig. 1B and S1B ). These results clearly demonstrate that Tg(MHM2D23-88)/Prnp 0/0 mice inoculated with 22L prions developed prion disease while those inoculated with RML prions were disease-free.
MHM2
Sc D23-88 is detectable in the brains of terminally ill, 22L-inoculated Tg(MHM2D23-88)/Prnp 0/0 mice
We investigated PK-resistant PrP in the brains of 22L-inoculated Tg(MHM2D23-88)/Prnp 0/0 , Tg(MHM2D23-88)/ Prnp 0/+ and Prnp 0/+ mice using Western blotting. MHM2D23-88 was reported to be overexpressed in brains about 4-times more than wild-type PrP C in the hamster brain [10] , thus giving rise to stronger signals for total PrP in Tg mice than in non-Tg Prnp 0/+ mice on Western blotting with M20 anti-PrP antibodies ( Fig. 2  and 3, 1 st panel). M20 antibodies were raised against a C-terminal peptide of PrP, and are therefore able to detect both wild-type PrP and MHM2D23-88. M20 antibodies also detected PK-resistant PrP in the brains of 22L-inoculated, terminally ill Tg(MHM2D23-88)/Prnp 0/0 , Tg(MHM2D23-88)/Prnp 0/+ and Prnp 0/+ mice (Fig. 2, 2 nd panel). The PK-resistant PrP in Tg(MHM2D23-88)/ Prnp 0/0 and Tg(MHM2D23-88)/Prnp 0/+ mice was recognized by 3F4 anti-PrP antibody (Fig. 2, 4 th panel), which is able to detect only the mutant protein (Fig. 2, 3 rd panel), indicating that MHM2D23-88 was converted into MHM2 Sc D23-88 in 22L-inoculated Tg(MHM2D23-88)/Prnp 0/0 and Tg(MHM2D23-88)/ Prnp 0/+ mice. MHM2 Sc D23-88 was undetectable in the brains of asymptomatic Tg(MHM2D23-88)/Prnp 0/0 mice, which were sacrificed at 337 dpi with 22L prions (Fig. 2, 4 th panel). In contrast, terminally ill Tg(MHM2D23-88)/Prnp 0/+ mice, which were sacrificed at 272-285 dpi with 22L prions, already accumulated MHM2 Sc D23-88 in their brains (Fig. 2, 4 th panel). These results indicate that the conversion of MHM2D23-88 into MHM2 Sc D23-88 was enhanced (Fig. 3, 2 nd panel). The PK-resistant PrP in Tg(MHM2D23-88)/ Prnp 0/+ mice was also detected with 3F4 antibody (Fig. 3, 4 th panel), indicating that MHM2D23-88 was converted into MHM2 Sc D23-88 in Tg(MHM2D23-88)/Prnp 0/+ mice inoculated with RML prions. No PK-resistant PrP was observed in the brains of Tg(MHM2D23-88)/Prnp 0/0 mice, which were inoculated with RML prions and sacrificed 419, 755, and 782 dpi, by Western blotting with M20 and 3F4 antibodies (Fig. 3, 2 nd and 4 th panels). RML prions and sacrificed at 591 dpi. None of the indicator mice inoculated with the single brain homogenate from the Tg(MHM2D23-88)/Prnp 0/0 mouse became sick by 365 dpi (Table 3) . PrP Sc was also undetectable in the brains of indicator mice sacrificed at 365 dpi (Fig. 5) . In contrast, single brain homogenates from RML-inoculated, terminally ill Prnp 0/+ and Tg(MHM2D23-88)/Prnp 0/+ mice caused the disease in indicator mice at 14765 and 14465 dpi, respectively ( . We purified recombinant full-length MHM2 and MHM2D23-88, both of which were tagged with 66His (Fig. 6A ). They were incubated with RML-or 22L-infected brain homogenates, in which similar amounts of PrP Sc (RML) and PrP Sc (22L) were included (Fig. 6B) , and then subjected to a pull-down assay using Protein G-coupled antibodies against the 66His tag. Fulllength MHM2 pulled down both PrP Sc (RML) and PrP Sc (22L) (Fig. 6B) . However, PrP Sc (22L) was pulled down more abundantly than PrP Sc (RML) (Fig. 6B) . Recombinant MHM2D23-88 also pulled down PrP Sc (RML) and PrP Sc (22L) (Fig. 6B) . However, only a tiny amount of PrP Sc (RML) was pulled down with MHM2D23-88 (Fig. 6B) . In contrast, recombinant MHM2D23-88 pulled down a much higher amount of PrP Sc (22L) (Fig. 6B) .
Discussion
In the present study, we showed that intracerebral inoculation with the brain homogenate from RML-infected, terminally ill wild-type mice never caused the disease in Tg(MHM2D23-88)/ Prnp 0/0 mice for up to 730 days. No MHM2 Sc D23-88 was detectable in their brains. We also failed to detect any prion infectivity in the brain of a Tg(MHM2D23-88)/Prnp 0/0 mouse sacrificed at 591 days after inoculation. These results are consistent with those previously reported by others [9, 10] . In contrast, we found that Tg(MHM2D23-88)/Prnp 0/0 mice developed prion disease after intracerebral inoculation with the brain homogenate from 22L-infected, terminally ill wild-type mice, with abundant accumulation of MHM2 Sc D23-88 and high prion infectivity present in their brains. These results show that MHM2D23-88 is converted into MHM2 Sc D23-88 in Tg(MHM2D23-88)/Prnp 0/0 mice after inoculation with 22L prions. We also showed that the similarly prepared brain homogenates from terminally ill, RMLand 22L-inoculated wild-type mice contained similar infectious doses of RML and 22L prions. This excludes the possibility that unsuccessful detection of MHM2 Sc D23-88 in the brains of RMLinoculated Tg(MHM2D23-88)/Prnp 0/0 mice might be due to lower infectious doses of RML prions being inoculated. It rather suggests that MHM2D23-88 is converted into MHM2 Sc D23-88 less efficiently by RML prions than by 22L prions.
Tg(MHM2D23-88)/Prnp 0/0 mice inoculated with 22L prions developed the disease with accumulation of MHM2 Sc D23-88 in their brains, indicating that MHM2 Sc D23-88 lacking the Nterminal residues 23-88 is neurotoxic. However, brain spongiosis was milder in terminally ill Tg(MHM2D23-88)/Prnp 0/0 mice than in terminally ill Prnp 0/+ and Tg(MHM2D23-88)/Prnp 0/+ mice, suggesting that MHM2 Sc D23-88 might not be fully toxic. Sonati et al. recently reported that the N-terminal region of PrP C mediates a neurotoxic signal originating from the C-terminal globular domain bound with anti-PrP antibodies [15] . It is thus possible that the Nterminal residues might also play a role in the neurotoxicity of wild-type PrP Sc . Wild-type indicator mice intracerebrally inoculated with the brain homogenate from a 22L-inoculated, terminally ill Tg(MHM2D23-88)/Prnp 0/0 mouse developed the disease significantly later than those inoculated with the brain homogenates from 22L-inoculated, terminally ill Tg(MHM2D23-88)/Prnp 0/+ and Prnp 0/+ mice. These results indicate that, while MHM2 Sc D23-88 is infectious, it is less infectious than wild-type PrP Sc .
Indistinguishable symptoms and PrP
Sc with the same PK digestion and glycosylation patterns were observed in all diseased indicator mice. These suggest that biological properties of 22L prions might not be altered even after the passage in Tg(MHM2D23-88)/ Prnp 0/0 mice. Rather, the slightly longer incubation times in indicator mice inoculated with the Tg(MHM2D23-88)/Prnp 0/0 homogenate might be due to the chimeric residues in MHM2 Sc D23-88. Indeed, full-length MHM2 Sc was shown to be slightly less infectious than wild-type PrP Sc in mice overexpressing wild-type mouse PrP C [9] . Alternatively, lack of the N-terminal residues in MHM2 Sc D23-88 might be responsible for the longer incubation times.
Prnp 0/0 mice used in this study ectopically express Dpl in their brains [16, 17] . It was reported that transgenic overexpression of Dpl did not modify incubation times and brain pathologies in Prnp +/+ mice infected with RML prions [18] . Prnp 0/+ mice with and without the ectopic expression of Dpl were also reported to display indistinguishable pathologies after infection with 301V BSE prions [19] . It is thus unlikely that Dpl affects the susceptibility of Tg(MHM2D23-88)/Prnp 0/0 mice to RML and 22L prions.
Tg(MHM2D23-88)/Prnp 0/0 mice inoculated with RML and 22L prions showed longer incubation times. Particularly, RMLinoculated Tg(MHM2D23-88)/Prnp 0/0 mice were free of the disease-specific symptoms for up to 730 days. It is known that sequence differences between PrP C in recipient animals and PrP Sc in an inoculum create a prion transmission barrier, causing elongation of incubation times [20] . Sc (RML) to MHM2D23-88. Different strain-specific susceptibility was also reported in Prnp 0/0 mice transgenically expressing mouse PrP with a serine residue at codon 170, PrP-170S [23] , or ovine PrP with a valine residue at codon 136, OvPrP-V136 [24] . Tg(PrP-170S)/Prnp 0/0 mice were highly resistant to RML and 79A prions, but susceptible to 22L and ME7 prions [23] . Only a very small number of the mice inoculated with RML and 79A prions showed brain accumulation of PrP Sc -170S [23] . In contrast, all mice inoculated with 22L and ME7 prions accumulated PrP Sc -170S in their brains [23] . Tg(OvPrP-V136)/Prnp 0/0 mice were susceptible to SSBP1 prions, but resistant to CH1641 prions [24] . OvPrP Sc -V136 was accumulated in the brains of the mice inoculated with SSBP1 prions [24] . These results suggest that strain-specific differential susceptibility in these mice is also due to different conversion efficiency of the host PrP C s into their PK-resistant isoforms. [27] . MHM2D23-88 lacks residues 23-31, suggesting that the reduced binding of MHM2D23-88 to PrP Sc s might be partly due to the lack of residues 23-31. However, Tg(PrPD32-93)/Prnp 0/0 and Tg(MHM2)/Prnp 0/0 mice were also reported to have reduced susceptibility to RML prions [9] , suggesting that the other deleted region(s) and the chimeric region also might be relevant to the binding of MHM2D23-88 to PrP Sc . It is thus of interest to compare the binding potential of PrP-170S and OvPrP-V136 to PrP
Sc from different prion strains. The conformational selection model of prion strains also has been proposed as a mechanism to explain strain-specific susceptibility [28, 29] . This model postulates that the inoculated PrP Sc selects the host PrP C as a substrate for conversion due to its conformational compatibility with the host PrP C [28, 29] . Conformational incompatibility between the inoculated PrP Sc and the host PrP C thus leads to unsuccessful or insufficient conversion of the host PrP C into its PK-resistant isoform. Indeed, accumulating lines of evidence suggest that PrP Sc is folded in a strain-specific conformation [30] . Nuclear magnetic resonance studies of recombinant PrPs suggest that the N-terminal domain, including the deleted residues and chimeric residues in MHM2D23-88, confers structural stability within the C-terminal globular domain [31, 32] . It is thus possible that MHM2D23-88 adopts a different conformation from that of wild-type PrP C , and that the adopted conformation of MHM2D23-88 still remains compatible with PrP Sc (22L), but not with PrP Sc (RML). The conformational selection model might also explain the different responsiveness of OvPrP-V136 and PrP-170S to different prion strains [23, 24] .
It was shown that the region corresponding to the chimeric region is exposed in PrP C molecules, but hidden in PrP Sc molecules [33, 34, 35] , and that the octapeptide repeat region of residues 51-90 is trypsin-sensitive in PrP C , but trypsin-resistant in PrP Sc [36] . These results indicate that upon the conversion of PrP C into PrP Sc , a marked conformational change occurs within the N-terminal domain. Interestingly, the N-terminal domain of PrP C is highly flexible and displays a marked conformational heterogeneity [32, 33, 37] . It is thus also possible that lack of residues 23-88 and insertion of the chimeric residues might reduce the N-terminal conformational heterogeneity of MHM2D23-88, and that the reduced conformational heterogeneity might render MHM2D23-88 resistant to RML but still susceptible to 22L prions.
The N-terminal domain was shown to be important for internalization of PrP C [38] . The conversion of PrP C into PrP Sc has been suggested to occur on the cell surface and/or along the endocytic pathway to lysosomes [39, 40] . Thus, defective internalization of MHM2D23-88 might lead to the insufficient conversion of MHM2D23-88 to MHM2 Sc D23-88. However, it remains unknown how internalized PrP C can undergo strain specific conversion.
Tg(MHM2D23-88)/Prnp 0/+ mice showed shorter incubation times than Prnp 0/+ mice after inoculation with RML prions. This is consistent with the previously reported results [9, 10] 
